Saturday 19 January 2019 - 06:33
In Business 39 Years - Since 1980
New Price Reductions for Nine Products - As Much As 33% -- January 11, 2019.
FREE SHIPPING TO THE U.S. AND 33 OTHER COUNTRIES! [Read more].
Search:
R-1234 Roscovitine, Free Base, >99%
Related Terms : [CYC202] [Seliciclib] [6-Benzylamino-2[(R)-(1'-ethyl-2'-hydroxyethylamino)]-9-isopropylpurine]
- Size
- US $
- €
- £
- ¥
- 10 mg
- 49
- 43
- 38
- 5,400
- In stock
- 25 mg
- 67
- 58
- 51
- 7,400
- In stock
- 50 mg
- 128
- 112
- 99
- 14,100
- In stock
- 100 mg
- 169
- 148
- 131
- 18,600
- In stock
- 200 mg
- 224
- 196
- 173
- 24,600
- In stock
- 300 mg
- 294
- 258
- 228
- 32,300
- In stock
- 1 g
- 649
- 570
- 503
- 71,200
- In stock
- 2 g
- 1,110
- 975
- 861
- 121,900
- In stock
- 5 g
- 1,975
- 1,736
- 1,532
- 216,800
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 354.45
- C19H26N6O
- [186692-46-6]
- M.I. 14: 10240
Storage: Store at or below -20 ºC. Solubility: Prepare initial stock solutions in DMSO (soluble at 200 mg/mL) or ethanol (soluble at 200 mg/mL) for in vitro use; solubility in water is low. Appearance: White to off-white powder. Disposal: A.
- Roscovitine is a potent inhibitor of p34cdc2 (IC50 = 0.2 µM). Also inhibits p33cdk2 and p33cdk5. Havlicek, L., et al. "Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds." J. Med. Chem. 40: 408-412 (1997).
- NOTE: The word "Roscovitine" inherently means the R-isomer.
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
